Literature DB >> 25646577

Interactions of antitumour Sialyl Lewis X liposomes with vascular endothelial cells.

Anna Alekseeva1, Marina Kapkaeva2, Olga Shcheglovitova2, Ivan Boldyrev1, Galina Pazynina1, Nicolai Bovin1, Elena Vodovozova3.   

Abstract

Recently, we showed that tetrasaccharide selectin ligand SiaLeX provided targeted delivery of liposomes loaded in the bilayer with melphalan lipophilic prodrug to tumour endothelium followed by severe injury of tumour vessels in a Lewis lung carcinoma model. Here, we study the impact of SiaLeX ligand on the interactions of liposomes with human umbilical vein endothelial cells (HUVEC) using flow cytometry, spectrofluorimetry and confocal microscopy. Liposomes composed of egg phosphatidylcholine/yeast phosphatidylinositol/1,2-dioleoyl glycerol ester of melphalan, 8:1:1, by mol, and varying percentages of lipophilic SiaLeX conjugate were labelled with BODIPY-phosphatidylcholine. The increase in SiaLeX content in liposomes led to a proportional increase in their uptake by cytokine-activated cells as opposed to non-activated HUVEC: for 10% SiaLeX liposomes, binding avidity and overall accumulation increased 14- and 6-fold, respectively. The early stages of intracellular traffic of targeted liposomes in the activated cells were monitored by co-localisation with the trackers of organelles. Endocytosis of SiaLeX liposomes occurred mostly via clathrin-independent pathways, which does not contradict the available literature data on E-selectin localisation in the plasma membrane. Using dual fluorescence labelling, with rhodamine-labelled phospholipid and calcein encapsulated at self-quenching concentrations, we found that SiaLeX liposomes undergo rapid (within minutes) internalisation by activated HUVEC accompanied by the disruption of liposomes; non-activated cells consumed a negligible dose of liposomes during at least 1.5h. Our data evidence the selective effect of SiaLeX formulations on activated endothelial cells and indicate their potential for intracellular delivery of melphalan lipophilic prodrug.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug targeting; E-selectin; Endocytosis; Melphalan lipophilic prodrug; Nanosized liposomes; Sialyl Lewis X

Mesh:

Substances:

Year:  2015        PMID: 25646577     DOI: 10.1016/j.bbamem.2015.01.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  The physiological and pathological roles and applications of sialyl Lewis x, a common carbohydrate ligand of the three selectins.

Authors:  Fanqi Jin; Fengshan Wang
Journal:  Glycoconj J       Date:  2020-02-15       Impact factor: 2.916

2.  Liposome Drug Delivery System across Endothelial Plasma Membrane: Role of Distance between Endothelial Cells and Blood Flow Rate.

Authors:  Olga E Glukhova
Journal:  Molecules       Date:  2020-04-18       Impact factor: 4.411

3.  Sialyl LewisX mimic-decorated liposomes for anti-angiogenic everolimus delivery to E-selectin expressing endothelial cells.

Authors:  Chanikarn Chantarasrivong; Yuriko Higuchi; Masahiro Tsuda; Yuuki Yamane; Mitsuru Hashida; Miku Konishi; Naoko Komura; Hiromune Ando; Fumiyoshi Yamashita
Journal:  RSC Adv       Date:  2019-07-02       Impact factor: 4.036

Review 4.  Endothelial Cell Adhesion Molecules- (un)Attainable Targets for Nanomedicines.

Authors:  Nenad Milošević; Marie Rütter; Ayelet David
Journal:  Front Med Technol       Date:  2022-04-07

Review 5.  Targeting Tumor Endothelial Cells with Nanoparticles.

Authors:  Yu Sakurai; Hidetaka Akita; Hideyoshi Harashima
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

6.  Novel Cationic Meso-Arylporphyrins and Their Antiviral Activity against HSV-1.

Authors:  Kseniya A Zhdanova; Inga O Savelyeva; Artem V Ezhov; Andrey P Zhdanov; Konstantin Yu Zhizhin; Andrey F Mironov; Natal'ya A Bragina; Alla A Babayants; Irina S Frolova; Nadezhda I Filippova; Nadezhda N Scliankina; Olga N Scheglovitova
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.